About Guanine nucleotide-binding protein subunit alpha-11
Guanine nucleotide-binding protein subunit alpha-11 (GNA11) is a protein
from Homo sapiens identified by UniProt accession
P29992, 359 residues long.
MolForge cross-references it against 0 known binders and
441 disease associations.
Target properties
| Protein name | Guanine nucleotide-binding protein subunit alpha-11 |
| UniProt accession | P29992 |
| Gene | GNA11 |
| Organism | Homo sapiens |
| Length | 359 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (441)
Diseases linked to this target (Open Targets).
- Familial isolated hypoparathyroidism · score 0.78
- familial hypocalciuric hypercalcemia 2 · score 0.67
- Familial hypocalciuric hypercalcemia type 2 · score 0.62
- congenital hemangioma · score 0.53
- melanoma · score 0.51
- familial hypocalciuric hypercalcemia · score 0.51
- Uveal Melanoma · score 0.50
- cutaneous melanoma · score 0.38
- phakomatosis pigmentovascularis · score 0.38
- autosomal dominant hypocalcemia · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P29992-F1 | alphafold | PREDICTED | 92.92 | — |
Amino-acid sequence (359 residues)
MTLESMMACC LSDEVKESKR INAEIEKQLR RDKRDARREL KLLLLGTGES GKSTFIKQMR IIHGAGYSEE DKRGFTKLVY QNIFTAMQAM IRAMETLKIL YKYEQNKANA LLIREVDVEK VTTFEHQYVS AIKTLWEDPG IQECYDRRRE YQLSDSAKYY LTDVDRIATL GYLPTQQDVL RVRVPTTGII EYPFDLENII FRMVDVGGQR SERRKWIHCF ENVTSIMFLV ALSEYDQVLV ESDNENRMEE SKALFRTIIT YPWFQNSSVI LFLNKKDLLE DKILYSHLVD YFPEFDGPQR DAQAAREFIL KMFVDLNPDS DKIIYSHFTC ATDTENIRFV FAAVKDTILQ LNLKEYNLV
Explore Guanine nucleotide-binding protein subunit alpha-11 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets